Atara Biotherapeutics, INC

Atara Biotherapeutics announced second quarter 2026 financial results and operational progress, including a productive FDA meeting for tabelecleucel and significant cost reductions.

Atara Biotherapeutics has appointed Kevin G. Sarney as interim CFO following the departure of Chief Accounting Officer Yanina Grant-Huerta.

Atara Biotherapeutics appoints Brian Cherry to its Board of Directors and confirms shareholder approval of all 2026 annual meeting proposals.

Atara Biotherapeutics reported Q1 2026 financial results, with a focus on operational progress and a potential path forward for tabelecleucel BLA resubmission with the FDA.

Atara Biotherapeutics provides an update on the regulatory path for tabelecleucel following a Type A meeting with the FDA, indicating a potential pathway for resubmission.

Atara Biotherapeutics has been notified by Nasdaq that it fails to meet the minimum $50 million market value requirement for continued listing.

Atara Biotherapeutics achieved a net income of $36.1 million for the first nine months of 2025, driven by significant cost reductions and strategic realignments, despite ongoing liquidity concerns.

Atara Biotherapeutics reported a net income for the first half of 2025, driven by strategic asset transfers and significant workforce reductions, while facing ongoing liquidity challenges.

Atara Biotherapeutics reports a net income of $38.0 million for Q1 2025, driven by commercialization revenue, and completes the transfer of manufacturing responsibilities to Pierre Fabre.

Atara Biotherapeutics reports third quarter 2024 results, highlighting commercialization revenue growth and progress in its clinical programs, including the acceptance of the tab-cel BLA by the FDA.

Atara Biotherapeutics' second quarter 2024 report highlights commercialization revenue growth and progress in clinical development, while also noting ongoing financial challenges.

Atara Biotherapeutics reports a net loss of $31.8 million for the first quarter of 2024, while progressing its T-cell immunotherapy programs and manufacturing capabilities.

Atara Biotherapeutics pauses CAR-T programs, focuses on tab-cel amid manufacturing challenges and strategic review.

Atara Biotherapeutics has amended its commercialization agreement with Pierre Fabre, expanding its reach to all global markets and securing a $20 million upfront payment, while also navigating financial challenges with workforce reductions.

Redmile Group, LLC and 1 other reported changes in beneficial ownership of Atara Biotherapeutics, Inc. common stock on July 22, 2026.

Atara Biotherapeutics director Brian Cherry was granted 24,000 restricted stock units as part of his compensation package.

Director William K. Heiden received a grant of 12,000 restricted stock units from Atara Biotherapeutics.

Director Matthew K. Fust was granted 12,000 restricted stock units in Atara Biotherapeutics, Inc.

Director Gregory A. Ciongoli was granted 12,000 restricted stock units by Atara Biotherapeutics, Inc.

Atara Biotherapeutics CEO AnhCo Nguyen sold 5,241 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Atara Biotherapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026.

Atara Biotherapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, with key proposals including the election of directors, executive compensation, and ratification of the company's independent auditor.

Atara Biotherapeutics schedules its 2025 Annual Meeting of Stockholders for June 10, 2025, to address director elections, executive compensation, and auditor ratification.

Atara Biotherapeutics issues a supplement to its proxy statement to clarify voting standards, the treatment of broker non-votes, and correct a scrivener's error for the upcoming 2024 Annual Meeting of Stockholders.

Atara Biotherapeutics is holding its annual meeting on June 10, 2024, seeking stockholder approval on several key proposals, including director elections, executive compensation, and a potential reverse stock split.

Atara Biotherapeutics is asking stockholders to approve a reverse stock split, elect directors, approve executive compensation, ratify the selection of its auditor, and approve its equity incentive plan at the upcoming annual meeting.

Redmile Group, LLC and its affiliates have updated their Schedule 13D filing to reflect changes in beneficial ownership of Atara Biotherapeutics, Inc. following the exercise of pre-funded warrants.

Redmile Group reports a change in beneficial ownership percentage of Atara Biotherapeutics due to shifts in the issuer's outstanding share count.

Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Atara Biotherapeutics common stock on May 7, 2026.

Panacea Venture entities, including James Huang, have updated their beneficial ownership in Atara Biotherapeutics, Inc., reporting a sale of shares and warrant exercises.

Redmile Group, LLC and its affiliates filed an amended Schedule 13D for Atara Biotherapeutics, Inc., updating beneficial ownership to 9.9% and adding Redmile Strategic Long Only Trading Sub, Ltd. as a reporting person.

Panacea Venture and its affiliates have increased their beneficial ownership in Atara Biotherapeutics, Inc. to 20.0% through recent open market purchases and warrant holdings.

Adage Capital Management, L.P. and its principals have reported beneficial ownership of 8.56% of Atara Biotherapeutics, Inc. common stock as of March 31, 2026.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 17.4% beneficial ownership stake in Atara Biotherapeutics, Inc.

EcoR1 Capital, LLC and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Atara Biotherapeutics, Inc. common stock.

Investment firm Redmile Group, along with its principal Jeremy C. Green and affiliated funds, has disclosed a combined beneficial ownership of 9.9% in Atara Biotherapeutics, Inc., including shares held directly and those issuable from pre-funded warrants.

Panacea Venture Healthcare Fund II, L.P. and its affiliated entities have disclosed a 9.5% passive beneficial ownership stake in Atara Biotherapeutics, Inc., holding 550,000 shares of common stock.